Amgen hangs hopes on hepatitis C.
Brower
V
V
D017277:Drug Approval; D016174:Hepacivirus / Q000201:enzymology; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007449:Investments; D011480:Protease Inhibitors / Q000627:therapeutic use; D020365:RNA Helicases; D012697:Serine Endopeptidases; D014481:United States; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors; D014779:Virus Replication / Q000187:drug effects; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
D016898:Interferon-alpha; D011480:Protease Inhibitors; D020365:RNA Helicases; D012697:Serine Endopeptidases; D017361:Viral Nonstructural Proteins; C060028:NS3 protein, flavivirus; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases